Publications by authors named "P Kosalaraksa"
Background: A next-generation, serum-free, highly purified Vero cell rabies vaccine, PVRV-NG2, is in development.
Methods: This multicenter, observer-blind, phase 3 study evaluated the immunogenicity and safety of PVRV-NG2, compared with two licensed rabies vaccines (purified Vero cell rabies vaccine [PVRV] and human diploid cell vaccine [HDCV]), as a pre-exposure prophylaxis (PrEP) regimen. Participants were randomized 3:1:1 to PVRV-NG2, PVRV, or HDCV, as a three-dose (Cohort 1; children and adults; day [D] 0, D7, and D28) or two-dose (Cohort 2; adults; D0 and D7) PrEP regimen.
Article Synopsis
- The study investigated how previous vaccinations for Yellow Fever (YF) and Japanese Encephalitis (JE) affect the effectiveness of the dengue vaccine candidate, TAK-003, in children aged 4-16 years.
- Out of 20,071 participants, different levels of vaccine efficacy were observed: 55.7% in those previously vaccinated for YF, 77.8% for JE, and 53.5% for those with no prior vaccinations, but these results were influenced by the regional distribution of dengue virus serotypes.
- Overall, the findings indicate that prior YF or JE vaccinations do not significantly impact the efficacy of TAK-003, which was well-tolerated across various epidemiological settings.
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
Lancet HIV
May 2024
Background: Coformulated bictegravir, emtricitabine, and tenofovir alafenamide is a single-tablet regimen and was efficacious and well tolerated in children and adolescents with HIV (aged 6 years to <18 years) in a 48-week phase 2/3 trial. In this study, we report data from children aged at least 2 years and weighing 14 kg to less than 25 kg.
Methods: We conducted this open-label, multicentre, multicohort, single-arm study in South Africa, Thailand, Uganda, and the USA.
Article Synopsis
- Transitioning from pediatric to adult healthcare is difficult for adolescents and young adults with perinatally-acquired HIV (AYA-PHIV) in Thailand.
- A study tracking treatment outcomes found that 93% of 811 eligible AYA-PHIV were alive, averaging 22.3 years old with 16.1 years of treatment; most received care in adult clinics.
- Among those who died (7%), the majority were from AIDS-related causes, highlighting the need for improved support systems during their transition into adulthood.
Purpose: This study aimed to investigate the antibodies against SARS-CoV-2 in children hospitalized due to COVID-19 during the era of pre-Omicron and Omicron variants.
Methods: This was a retrospective observational study conducted at a tertiary academic medical center in Thailand between June 2021 and August 2022. We collected the data of children aged under 18-year who were hospitalized from SARS-CoV-2 infection.